Certara, headquartered in Princeton, NJ, produces model-based pharmaceutical software.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $9.55 |
|---|---|
| 52-week range | $9.88 - $19.87 |
| 50-day moving average | $10.95 |
| 200-day moving average | $14.76 |
| Wall St. target price | $14.28 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.20 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $9.88 from 2024-11-19
| 1 week (2024-11-13) | -7.75% |
|---|---|
| 1 month (2024-10-18) | -13.41% |
| 3 months (2024-08-20) | -23.11% |
| 6 months (2024-05-20) | -39.61% |
| 1 year (2023-11-20) | -32.83% |
|---|---|
| 2 years (2022-11-18) | -34.44% |
| 3 years (2021-11-19) | 30.48 |
| 5 years (2019-11-17) | N/A |
Valuing Certara stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Certara's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Certara's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $79.2 million.
The EBITDA is a measure of a Certara's overall financial performance and is widely used to measure a its profitability.
To put Certara's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $372.8 million |
|---|---|
| Operating margin TTM | 6.74% |
| Gross profit TTM | $203.1 million |
| Return on assets TTM | 0.59% |
| Return on equity TTM | -2.95% |
| Profit margin | -8.34% |
| Book value | $6.55 |
| Market Capitalization | $1.7 billion |
TTM: trailing 12 months
We're not expecting Certara to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Certara's shares have ranged in value from as little as $9.88 up to $19.8702. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Certara's is 1.511. This would suggest that Certara's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Certara's beta into context you can compare it against those of similar companies.
Certara, Inc. , together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.